US00773J2024
US00773J2024
Spyre Therapeutics, Inc.
Loading chart...
Pure Price Volatility Risk (Market Swings)
The business itself is financially solid (Financial Health 65/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±180.0% p.a.) and steep historical drawdowns.
Volatility Risk
Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.
Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta
Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves approx. 3.1x as much as the broader market.
Beta (Market Relation)
3.11x
Above averageVolatility (5Y p.a.)
180.0% p.a.
5-Year HorizonMax Drawdown (5Y)
-98.7%
5-Year HorizonSharpe Ratio
-0.10
Return / RiskSpeculative / High Risk: Score Basis:
Multi-Horizon Risk & Performance Matrix
Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.
High Volatility
Timeframe | Volatility (p.a.) | Max Drawdown | Sharpe Ratio | Return (p.a.) |
|---|---|---|---|---|
| 1 Year | — | — | — | +351.9% |
| 3 Years | 73.6% | -74.0% | 1.15 | +86.9% |
| 5 Years | 180.0% | -98.7% | -0.1 | -16.3% |
| 10 Years | 136.3% | -99.0% | -0.07 | -6.9% |
Automated Risk & Health Notes (Red Flags)
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
High market risk: Beta of 3.11 indicates above-average volatility compared to the broader market.
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (180.0% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -99.0% in the extended horizon.
Corporate Governance & ISS Scores
Overall Governance Risk
9 ISS Score: 9 / 10
Audit Risk
10 ISS Score: 10 / 10
Board Risk
6 ISS Score: 6 / 10
Short Ratio
10.44